Eisai Preps Eritoran For Phase III Sepsis Trial Based On Phase II Mortality Reduction
This article was originally published in The Pink Sheet Daily
Executive Summary
Closest competitor appears to be Takeda, which plans Phase III study this summer for its own TLR4 inhibitor for severe sepsis.
You may also be interested in...
AstraZeneca Licenses Protherics Sepsis Treatment
AstraZeneca will take the polyclonal antibody fragment CytoFab into Phase III trials in 2007, following a manufacturing upgrade.
AstraZeneca Licenses Protherics Sepsis Treatment
AstraZeneca will take the polyclonal antibody fragment CytoFab into Phase III trials in 2007, following a manufacturing upgrade.
Xigris "Dear Doctor" Letter Follows Termination Of Pediatric Sepsis Trial
Lilly says a data monitoring committee determined that Xigris was "highly unlikely to show improvement over placebo" in the study's primary endpoint – composite time to complete organ failure resolution.